To further support the prominent activity of Skinmimics® Evonik has performed a new study.
Skinmimics® is a unique, multi-lamellar delivery system based on high-tech biomimetic ingredients for improved bioavailability. It is a skin-identical composition made up of specific long chain ceramides, non-animal derived cholesterol and free fatty acid. This composition is combined with unique signalling molecules (Sphingokines®). The various ceramides contained in Skinmimics® are based on Evonik’s advanced and deep knowledge in this technology.
Earlier in vitro and in vivo studies have already shown that Skinmimics® displays a 3-in-1 benefit, especially on mature skin. It provides protection by correction of membrane defects in the stratum corneum by topical application of skin barrier lipids. Prevention, the second benefit, is shown by the induction of skin lipid synthesis and epidermal differentiation for improved barrier function from within. Finally, Skinimimcs® stimulates and supports the epidermal renewal by activation of the skin’s natural water management system. This leads to skin regeneration.
Now, an additional in vivo study using confocal Raman Spectroscopy fosters the previous findings. It could be shown that Skinmimics® significantly replenishes skin’s own protection barrier. Furthermore, this active is able to revitalize normal to dry skin by optimizing
the total epidermal moisturizing system.
Taking all study results into account Skinmimics® is an attractive ingredient for skin barrier protection formulations, skin regeneration and nourishing products. It fits very well with market concepts developed for mature skin.
For more information, contact:
Lisa Dierks, Associate Marketing Manager Communication/Personal Care
Evonik Industries AG
Phone: +49 201 173-3170, Lisa.Dierks@evonik.com or visit our website www.evonik.com/personal-care .
Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. In 2010 about 80 percent of the Group’s chemicals sales came from activities where it ranks among the market leaders. Evonik benefits specifically from its innovative prowess and integrated technology platforms.
Evonik is active in over 100 countries around the world. In fiscal 2010 more than 34,000 employees generated sales of around €13.3 billion and an operating profit (EBITDA) of about €2.4 billion.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.